Ideas to Action:

Independent research for global prosperity

CGD Policy Blogs

Current search

Reset Filters

Topic

Expert

Date

 

July 25, 2006

Costs of poor forecasting = 10 million antimalarials

Like the boy who cried wolf, the international public health community has a serious credibility problem: estimates of demand for antimalarial drugs have once again proven to be wildly optimistic, leaving the manufacturer, Sanofi-Aventis, holding 10 million tablets of artesunate that were produced but not purchased within the "sell by" date. Now, Sanofi has two bad options: throw them away or give them away - if they can find any takers.

Ruth Levine
July 24, 2006

Health Technologies Require Policy Innovations

Health technologies have value if and only if they are used -- or, as we wrote in Millions Saved after reviewing 17 large-scale successes in global health, what's needed is "innovation within an effective delivery system, at a sustainable price." That simple observation bears repeating as a caravan of new drugs, diagnostic products and vaccines for diseases that predominantly affect poor countries move through the R&D pathway, and yet face speed bumps when it's time for scaled-up manufacture and

Ruth Levine
July 23, 2006

Economics of Big Pharma

Peter Huber of the Manhattan Institute's Center for Legal Policy has just published a great overview of the economic rationale for the widely unpopular practices of the pharmaceutical industry, aptly titled "Of Pills and Profits: In Defense of Big Pharma." He argues:

July 21, 2006

AIDS & Circumcision in South Africa

The Washington Post has an excellent - if somewhat depressing - article on the tragic irony of a new law banning circumcision of boys under 16 in South Africa despite evidence that the practice reduces the risk of contracting HIV by 60%:

cgdadmin
July 21, 2006

AIDS & Circumcision in South Africa

The Washington Post has an excellent - if somewhat depressing - article on the tragic irony of a new law banning circumcision of boys under 16 in South Africa despite evidence that the practice reduces the risk of contracting HIV by 60%:

July 19, 2006

Gates funds HIV vaccine research

From the foundation's press release:

The Bill & Melinda Gates Foundation today announced 16 grants totaling $287 million to create an international network of highly collaborative research consortia focused on accelerating the pace of HIV vaccine development.

The grants will support a range of innovative approaches for designing an effective HIV vaccine, and bring together more than 165 investigators from 19 countries to tackle some of the biggest scientific challenges facing the field.

Pages